Resonance Health is a healthcare company listed on the Australian Stock Exchange (ASX:RHT). Resonance Health provides quantitative MRI based technology for the diagnosis and monitoring of human disease. Accurate imaging end points are increasingly used in clinical trials, providing quantitative and direct evidence for regulatory submissions.
Resonance Health's image analysis laboratory provides quality certified central image analysis services to the clinical community and to clinical trials.
FerriScan was the first product brought to market and provides an accurate
non-invasive assessment of liver iron, largely removing the need for a liver biopsy in many patients with iron overload conditions. Research and development into pipeline products are focused on the key markets associated with liver disease.